Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer Group
Configuration
| Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,126.70 | 865.19 | 210.52 | -150.21 | 37.82 | 0.00 | 20.1121 | -0.37 | -1.0628 | -23.6434 | -0.09 | -0.08 | 7.1387 | - - | ||
| Maximum | - - | - - | - - | 458,604.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.01 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
| Nuvalent, Inc. NUVL | 86.88 | -3.30 -3.66% | 772 vs. 521 | 6,064.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 69.00 | ||
| Chinook Therapeutics, Inc. KDNY | 40.39 | 0.09 0.22% | 3,281 vs. 2,044 | 2,708.00 | 1.00 | -66.00 | -61.00 | -546.00 | -0.9400 | -10.2719 | 0.0000 | 0.5704 | -66.4127 | -0.1875 | -0.1370 | 5.7224 | 67.00 | ||
| DICE Therapeutics, Inc. DICE | 47.55 | 0.03 0.06% | 4,332 vs. 1,753 | 2,270.00 | 0.00 | -34.00 | -30.00 | -248.00 | -0.7400 | -15.7831 | 0.0000 | 0.0000 | 0.0000 | -0.0671 | -0.0632 | 25.6858 | 47.00 | ||
| Vaxcyte, Inc. PCVX | 86.83 | -5.85 -6.31% | 4,600 vs. 1,091 | 10,822.00 | 0.00 | -95.00 | -171.00 | -1,019.00 | -0.8500 | -19.6094 | 0.0000 | 0.0000 | 0.0000 | -0.0479 | -0.0454 | 17.2498 | 124.00 | ||
| Revolution Medicines, Inc. RVMD | 55.13 | -2.24 -3.90% | 1,944 vs. 1,156 | 9,273.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.